We are involved in all of the phases of the health product and/or service life cycle (medicine, medical devices, raw materials for pharmaceutical use, in vitro diagnostic devices, biological and biotechnological products, cosmetics, patient health data, clinical trials, e-health, etc.) and for all French and international operators (pharmaceutical laboratories, medical equipment manufacturers, public or private research institutes, academic stakeholders, biotechnology companies, investors, service providers, competitiveness clusters, etc.).
We assist our clients in three strategic dimensions:
Our assets? Lawyers coming from the pharmaceutical industry or from the field ofmedical equipment finance and senior public administration, a strong relationships with administrative bodies in the field of health, new technologies and personal data protection (CNIL) or professional organizations (including LEEM) and a network of international clients and partners which enable us to remain at the forefront of developments in the health sector.
Subscription:
On this topic and many others, please let us know your main areas of interest
to receive selected information.
De Gaulle Fleurance advised Caisse d’Epargne Ile de France and Banque Populaire Rives de Paris on the financing of Abenex’s investment in Phenomen
PRESS RELEASE Phenomen, a French specialist in cancellation insurance brokerage, is v...
De Gaulle Fleurance advised the arranger « Caisse d’Epargne et de Prévoyance Auvergne Limousin » and other lenders in the financing of Eurazeo’s investment in 2BSI
PRESS RELEASE Eurazeo, a French investment company, has acquired a stake in 2BSI th...
